Tango Therapeutics, Inc. 8K

Tango Therapeutics reported Q2 2026 results, highlighted strong cash reserves, positive Phase 1/2 pancreatic cancer data for vopimetostat combinations supporting Phase 3 planning, upcoming clinical milestones, and key executive and board appointments.

On August 11, 2026, Tango Therapeutics, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, highlighted by a strengthened cash position of $1.0 billion, increased R&D and G&A expenses leading to a higher net loss, and provided significant business updates including highly positive Phase 1/2 data for vopimetostat in combination with daraxonrasib in MTAP-deleted, RAS‑mutant pancreatic cancer that is expected to support a Phase 3 registrational path, plans to present additional data at the 2026 ESMO Congress, and key leadership changes with the appointment of Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board as the company prepares for late-stage development and commercialization.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

8K

Source Type

fda

Accession

0001193125-26-343434

Alert Tier

6